Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Retina. 2015 Jul;35(7):1303–1314. doi: 10.1097/IAE.0000000000000483

Table 9.

Change in visual acuity from baseline at Year 1 stratified by number of discrepant treatments in CATT as needed dosing group patients.

Overall Ranibizumab Bevacizumab
Number of missed
treatment in Year 1		 n Mean VA
change from
baseline at 1
Year (SD)		 n Mean VA
change from
baseline at 1
Year (SD)		 n Mean VA
change from
baseline at 1
Year (SD)
1–2 191 7.7 (12.5) 99 8.0 (12.8) 92 7.3 (12.2)
3–4 157 7.2 (13.4) 94 6.6 (12.7) 63 8.0 (14.4)
5+ 122 6.1 (13.4) 63 5.8 (12.7) 59 6.3 (14.3)
P-value 0.58 0.57 0.78